Navigation Links
Xoft to Present at the 26th Annual JPMorgan Healthcare Conference
Date:1/3/2008

CEO to Provide Update on the Clinical and Commercial Adoption of the

Axxent(R) Electronic Brachytherapy System

FREMONT, Calif., Jan. 3 /PRNewswire/ -- Xoft, Inc., developer of the Axxent(R) Electronic Brachytherapy System, a proprietary cancer treatment platform that utilizes X-rays to deliver non-radioactive, isotope-free radiation therapy directly to cancer sites, today announced that it will present at the 26th Annual JPMorgan Healthcare Conference. Xoft president and CEO Michael Klein will present on Thursday, January 10, 2008, at 7:30am PST at The Westin St. Francis Hotel in San Francisco.

"We are excited to have the opportunity to provide an update on the adoption of this exciting new method of delivering internal radiation therapy since we went fully commercial in Q4 of 2007," said Klein. "With breast cancer, the first FDA cleared indication for the Axxent System, we are already seeing excellent clinical results at the 10 initial clinical sites and more than a dozen commercial sites that have committed since we went commercial. Combined with strong awareness among the oncology community and the recent establishment of Medicare payment for Electronic Brachytherapy in the outpatient hospital setting, we expect rapid and widespread commercial adoption, making it available to women who want to take advantage of breast conserving therapy."

Cleared by the U.S. Food & Drug Administration (FDA) for the treatment of early stage breast cancer, the Axxent System is designed to deliver therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue. Eliminating the need for heavily shielded environments, it gives radiation oncologists the flexibility to deliver therapy in a broader range of clinical settings.

Use of the Axxent Electronic Brachytherapy System also provides the opportunity to reduce the time required for radiation therapy for early stage breast cancer from seven weeks (for external radiation therapy) down to five days. As a result, tens of thousands of patients will have greater access to therapy that is delivered more easily and conveniently. This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy.

The American Medical Association (AMA) Common Procedural Terminology (CPT) Editorial Panel recently approved a CPT Code for the use of electronic brachytherapy. Effective July 2007, the CPT code for electronic brachytherapy is included in the AMA CPT 2008 codebook. Additionally, the Category III CPT Code 0182T: high dose rate electronic brachytherapy, per fraction, has been assigned a New Technology Ambulatory Payment Classification (APC). The APC payment applies to the outpatient hospital and ambulatory surgical center settings and includes the high dose rate electronic brachytherapy radiation treatment and the cost of the X-ray source.

About Xoft, Inc.

Xoft is developing leading-edge new technologies for the practice of radiation oncology through Electronic Brachytherapy, which utilizes proprietary miniaturized x-ray tube technology. The Axxent(R) Electronic Brachytherapy System, Xoft's first treatment system, is currently being used in Accelerated Partial Breast Irradiation (APBI) for the treatment of early-stage breast cancer. This solution provides a therapeutic dose of intracavitary radiation directly to the region at risk without the complex handling and resource logistics necessary when performing brachytherapy using radioactive isotopes.

Axxent is a registered trademark of Xoft, Inc.


'/>"/>
SOURCE Xoft, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Danaher to Present at J.P. Morgan Healthcare Conference
2. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
3. Thoratec Presentation at JP Morgan Conference to be Webcast
4. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
5. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
6. CryoLife to Present at OneMedPlace Finance Forum
7. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
8. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
9. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
10. Beckman Coulter to Present at the JPMorgan Healthcare Conference
11. Thermo Fisher Scientific to Present at the 26th Annual JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... Ca (PRWEB) , ... May ... ... (PSCs) offer an unlimited source of human cardiovascular cells for research and ... differentiation methods makes it possible to generate large numbers of cardiomyocytes (hPSC-CMs). ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... ... sources for advanced technology applications, has announced a facility expansion to accommodate its ... 3,000 square feet of new workspace and renovation of the existing areas. The ...
(Date:5/22/2017)... MA (PRWEB) , ... May 22, 2017 , ... Stratevi, ... has expanded to the East Coast. It has opened an office in downtown Boston ... therapies are finding it increasingly more important to generate evidence on the value they ...
(Date:5/19/2017)... ... , ... In response to the strong base of evidence supporting the use ... release of their Gait Trainer 3 with an Integrated Music Therapy option. This is ... in rehabilitating individuals with cerebral palsy, traumatic brain injury, stroke and Parkinson’s disease. ...
Breaking Biology Technology:
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):